The landmark 2017 Cell study (Baar MP et al., PMID: 28340339) demonstrated that: (1) FOXO4 protein specifically accumulates in senescent cells where it binds to p53 and prevents p53 from triggering apoptosis (this is the specific mechanism being targeted)
(2015): in studies of drugs approved between 2010 and 2012, just 45 percent of trial participants in small molecule trials were women, but they represented 65 percent of participants in biologic trials (based on Drugs@FDA data)
A recent study showed the upregulation of the expression of programmed death-ligand 1 (PD-L1) under hypoxia [59]
Use our BPC-157 dosage calculator for complete protocols
Where most recovery options work on symptoms, BPC-157 acts at the tissue level, promoting new blood vessel formation, recruiting repair cells, and modulating the inflammatory cascade so your body can do what it was already trying to do, faster